{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:53:56Z","timestamp":1780649636096,"version":"3.54.1"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>With the current therapeutic modalities available to endocrinologists, control of GH and IGF\u2010I is now possible in almost all patients with acromegaly with multi\u2010modality therapy. Despite biochemical control of GH and IGF\u2010I, patients with acromegaly continue to experience impaired quality of life. Although there are likely multiple factors contributing to this dissatisfaction with current medical therapies, in particular the widely utilised injectable long\u2010acting somatostatin receptor ligands (iSRL), is a contributor. The iSRLs require intramuscular or deep subcutaneous injection with a wide bore needle that can be complicated by injection site pain, erythema, subcutaneous nodule formation, and for most individuals require attendance with a healthcare professional every 28 days to safely administered the medication. Two oral SRL (oSRL) formulations, Oral Octreotide Capsules and Paltusotine have been developed with clinical studies showing them to have promise as a therapeutic alternative to iSRL.<\/jats:p>","DOI":"10.1111\/cen.15193","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T07:15:04Z","timestamp":1735542904000},"page":"288-290","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality?"],"prefix":"10.1111","volume":"102","author":[{"given":"David S.","family":"McLaren","sequence":"first","affiliation":[{"name":"Departments of Endocrinology, Leeds Centre for Diabetes &amp; Endocrinology Leeds Teaching Hospital NHS Trust Leeds UK"},{"name":"Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM) University of Leeds Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6414-5629","authenticated-orcid":false,"given":"Nikolaos","family":"Kyriakakis","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Leeds Centre for Diabetes &amp; Endocrinology Leeds Teaching Hospital NHS Trust Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1633-4155","authenticated-orcid":false,"given":"Khyatisha","family":"Seejore","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Leeds Centre for Diabetes &amp; Endocrinology Leeds Teaching Hospital NHS Trust Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lynch","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Leeds Centre for Diabetes &amp; Endocrinology Leeds Teaching Hospital NHS Trust Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-6109","authenticated-orcid":false,"given":"Robert D.","family":"Murray","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Leeds Centre for Diabetes &amp; Endocrinology Leeds Teaching Hospital NHS Trust Leeds UK"},{"name":"Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM) University of Leeds Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1191"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00244-3"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0267"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.158"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13331"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2017-000570"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-020-00595-4"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","unstructured":"D.Ferone P.Freda L.Katznelson et al. \u201cOctreotide Subcutaneous Depot for Acromegaly: A Randomized Double\u2010Blind Placebo\u2010Controlled Phase 3 Trial ACROINNOVA 1 \u201dJournal of Clinical Endocrinology and Metabolism. Published ahead of print October 8 2024 dgae707 https:\/\/doi.org\/10.1210\/clinem\/dgae707.","DOI":"10.1210\/clinem\/dgae707"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1303-9"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4113"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00296-5"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa526"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01201-z"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac643"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae385"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.15193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T10:58:23Z","timestamp":1738580303000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.15193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,29]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/cen.15193"],"URL":"https:\/\/doi.org\/10.1111\/cen.15193","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,29]]},"assertion":[{"value":"2024-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}